Thyrocare Technologies Limited has informed the Exchange about additional capital infusion in Thyrocare Laboratories (Tanzania) Limited.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare Technologies has infused an additional USD 4,75,000 (approximately INR 4.33 Crores) into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Limited, by subscribing to Compulsorily Convertible Irredeemable Preference Shares (CCPS). This is a joint venture with the Kastipharm Group, operating in the diagnostic and healthcare services space. With this tranche, Thyrocare's total investment in the Tanzania entity has reached around INR 10 Crores, out of a board-approved limit of up to INR 15 Crores. The Tanzania subsidiary, incorporated in September 2023, reported a turnover of INR 1.84 Crores for calendar year 2025 and currently has a negative net worth of INR 0.32 Crores, indicating it is still in an early growth stage. The funds will be used to support business operations and working capital needs. Thyrocare's shareholding remains at 57.25% in equity and 100% in CCPS.
The infusion is small relative to Thyrocare's overall size and falls within a previously announced funding plan for the early-stage Tanzania business. Limited immediate impact on shareholders; the focus remains on whether the overseas venture scales up and turns profitable.